Business
Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022
MIAMI, April 01, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently
About this update from Fortress Biotech, Inc.
[{"type":"text","content":"MIAMI, April 01, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced a two-day summit hosted by the B. Riley Securities’ Healthcare Equity Research team, that will feature multiple programs from Fortress’ diversified pipeline. The events will be held virtually on Tuesday, April 5, and Wednesday, April 6, 2022, beginning at 1:00 p.m. ET each day. Registration link and webcast information: Please click here to register for the event.Following each event, the webcast will be available on the News / Events page, located within the Investors section of Fortress’ website, https://www.fortressbiotech.com/news-media/events, for approximately 30 days. Agenda: Day One: Tuesday, April 5, 2022 (1:00 p.m. – 3:00 p.m. ET) 1:00 p.m. ET - Opening Remarks and Fortress Strategy Lindsay Rosenwald, M.D., Chairman, President & Chief Executive Officer of Fortress Biotech; Mayank Mamtani, Head of HC Research, B. Riley Securities 1:30 p.m. ET - Panel #1 – Journey Medical Corporation (NASDAQ: DERM) Claude Maraoui, Co-Founder, President & Chief Executive Officer; Ernie De Paolantonio, Chief Financial Officer; Ramsey Alloush, General Counsel 2:00 p.m. ET - Panel #2 – Cyprium Therapeutics Charles Buchen, M.D., Chief Business Officer; Lung Yam, M.D., Ph.D., President & Chief Scientific Officer 2:30 p.m. ET - Panel #3 – UR-1 Therapeutics Raymond Zheng, Ph.D., President & Chief Scientific Officer; Scott Baumgartner, M.D., Interim Chief Medical Officer Day Two: Wednesday, April 6, 2022 (1:00 p.m. – 3:00 p.m. ET) 1:00 p.m. ET – Fortress Strategy – Execution and Value Generation Lindsay Rosenwald, M.D., Chairman, President & Chief Executive Officer of Fortress Biotech 1:30 p.m. ET - Panel #1 – Mustang Bio (NASDAQ: MBIO) Manuel Litchman, M.D., President & Chief Executive Officer; Knut Niss, Ph.D., Chief Technology Officer; Bruce Dezube, M.D., Senior Vice President, Head of Clinical Development; Eliot Lurier, C.P.A., Interim Chief Financial Officer 2:15 p.m. ET - Panel #2 – Checkpoint Therapeutics (NASDAQ: CKPT) James F. Oliviero, President & Chief Executive Officer; Garrett Gray, Chief Financial Officer About Fortress Biotech Fortress Biotech, Inc. (“F...